Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Arshad Hosseini"'
Autor:
Behnam Hasannejad-Asl, Hassan Hashemzadeh, Farkhondeh Pooresmaeil, Mehran Dabiri, Mohammad-Reza Pooresmaeil, Davoud Ahmadvand, Arshad Hosseini
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
IntroductionDuring the last decade, there has been a significant rise in the use of therapeutic antibodies or passive immunotherapy for treating various conditions like inflammation and cancer. However, these proteins face challenges reaching the bra
Externí odkaz:
https://doaj.org/article/5b8d13ba525b4be5842b0305ec777ae6
Autor:
Ali Majidi Yazdi, Arshad Hosseini, Seyed Mohammad Gheibihayat, Mohammad Beygi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Publikováno v:
Nanomedicine Journal, Vol 11, Iss 1, Pp 93-106 (2024)
Objective(s): Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli are the main pathogenic bacteria involved in severe, polymicrobial, and multidrug-resistant infections. For these infections to be overcome, lipid-based nanoparticles a
Externí odkaz:
https://doaj.org/article/e11775aea7ae465f8aabd55017bc39eb
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0306545 (2024)
IntroductionAccording to WHO, Breast cancer is widely considered to be the first or second cause of cancer-related death almost universally. Cell cycle disruption, either in the form of uncontrolled expression of cyclins or because of the suspension
Externí odkaz:
https://doaj.org/article/033d54a82ce340cfaa6defcd86b65822
Autor:
Saeedeh Darvishi, Nahid Atyabi, Arshad Hosseini, Pouria Omidi, Farhad Zaker, Arash Ghalyanchi Langeroudi, Siavash Moradi
Publikováno v:
Journal of Mazandaran University of Medical Sciences, Vol 28, Iss 168, Pp 29-39 (2019)
Background and purpose: MicroRNA regulation of cancer-related pathways has a major effect on cancer development. MiR-429 is a member of miR-200 family with an important role in metastasis. There are many studies on the association between miR-429 and
Externí odkaz:
https://doaj.org/article/b0c60163f23f43ba8de158a10c9c9a6d
Publikováno v:
Middle East Journal of Cancer, Vol 9, Iss 2, Pp 105-111 (2018)
Background: Breast cancer is the second leading cause of cancer death after lung cancer. Discovering molecular biomarkers is necessary for disease management that includes prognosis prediction and preventive treatment. The aim of this study is to eva
Externí odkaz:
https://doaj.org/article/ffe6ffc3b6e34f56b4f72b3b0573ef88
Publikováno v:
Journal of Cell and Molecular Research, Vol 9, Iss 1, Pp 6-15 (2017)
MicroRNAs by their structural complementarity capabilities have canonical roles in gene regulation. In this paper; we investigate expression of EGFR, MAP2K4 and E2F3 genes targeted by miR-141, a member of miR-200 family. EGFR, MAP2K4 and E2F3 were pr
Externí odkaz:
https://doaj.org/article/a2cbec6ca2e14d6b9edfa56ee4f32679
Autor:
Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, Sherko Nasseri, Kaveh Haji-allahverdipoor, Neda Rostami, Yaeren Hernandez, Safa Najafi, Neda Saraygord-Afshari, Arshad Hosseini
Publikováno v:
Pharmacological Reviews. 75:309-327
Autor:
Mohammad Mahmoudi Gomari, Neda Rostami, Davood Rabiei Faradonbeh, Hamid Reza Asemaneh, Giti Esmailnia, Shahriar Arab, Marziye Farsimadan, Arshad Hosseini, Nikolay V. Dokholyan
Publikováno v:
ProteinsREFERENCES. 90(11)
The binding of therapeutics to human serum albumin (HSA), which is an abundant protein in plasma poses a major challenge in drug discovery. Although HSA has several binding pockets, the binding site I on D2 and binding site II on D3 are the main bind
Autor:
Maryam Eini, Sepideh Parsi, Mahmood Barati, Golnaz Bahramali, Marziyeh Alizadeh Zarei, Jafar Kiani, Assad Azarnezhad, Arshad Hosseini
Publikováno v:
Avicenna Journal of Medical Biotechnology.
Background: An increasing number of studies have suggested that unveiling the molecular network of miRNAs may provide novel therapeutic targets or biomarkers. In this study, we investigated the probable molecular functions that are related to microRN
Publikováno v:
PLOS ONE. 17:e0279522
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) that currently lacks specific therapy options. Thus, chemotherapy continues to be the primary treatment, and developing novel targets is a top clinical focus. The and